ArticleCancer medicine2026
Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B-Cell Lymphoma: A Retrospective Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPrimary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma with heterogeneous clinical features and survival outcomes. Although most patients respond favorably to modern immunochemotherapy, reliable baseline prognostic indicators remain insufficiently defined.
methodsWe retrospectively analyzed 424 patients with histologically confirmed PB-DLBCL. Clinical characteristics, treatment patterns and survival outcomes were evaluated. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Prognostic factors were assessed by univariate and multivariate Cox regression analyses.
resultsWith a median follow-up of 36 months, the 3 year OS and PFS rates were 81.3% and 63.3%, respectively. In multivariate analysis, high-risk International Prognostic Index (IPI; score 3-5) was independently associated with inferior OS (HR 2.06, 95% CI 1.24-3.43, p = 0.006). For PFS, hypoalbuminemia (< 40 g/L) emerged as an independent predictor (HR 1.44, 95% CI 1.03-2.02, p = 0.035). Although failure to achieve complete remission and high Deauville score were associated with worse outcomes in univariate analyses, these post-treatment variables were not included in multivariable models.
conclusionPB-DLBCL often presents with advanced disease but demonstrates generally favorable survival in the rituximab era. Baseline IPI remains a robust predictor of OS, while hypoalbuminemia independently predicts disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.